Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Opus Genetics, Inc.NASDAQ: IRD
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities rises 310.5% from a year ago
Other non-current liabilities stood at $77.35M at the end of Q1 FY2026, up 310.5% from a year earlier and up 185.3% from the prior quarter.
Context
- Other non-current liabilities amounted to 115.8% of total assets at the end of Q1 FY2026, up 76.7 pp from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +310.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27.11M USD
- Year-over-year change
- +43.9%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.11M | +43.9% |
| FY2024 | 2024-12-31 | 18.84M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 other non-current liabilities of $77.35M is the highest of the 10 companies compared; the peer median is $8K.
- Its year-over-year change of +310.5% is the highest of 7, against a peer median of -57.7%.
- Other non-current liabilities amounts to 115.8% of total assets for IRD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $77.35M | +310.5% | — | 115.8% |
| Mar 2026 | $2.14M | +13.0% | +12.9% | 1.8% | |
| Mar 2026 | $1.77M | +27.0% | +31.8% | 0.7% | |
| Mar 2026 | $247K | -99.9% | -89.4% | 0.1% | |
| Mar 2026 | $26K | -16.1% | -70.8% | 0.0% | |
| Mar 2026 | $8K | -99.2% | -90.1% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | -$1 | — | — | 0.0% | |
| Peer median (excluding IRD) | $8K | -57.7% | -70.8% | 0.0% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.